SCHEMBL2536648

SCHEMBL2536648

O=Cc1cc(Oc2ccccc2)ccc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.50
▸ GAA P10253 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ ERN1 O75460 2/20 0.44
▸ LTA4H P09960 3/20 0.43
▸ TSHR P16473 1/20 0.43
▸ FFAR4 Q5NUL3 2/20 0.42
▸ GSTP1 P09211 1/20 0.42
▸ FFAR1 O14842 1/20 0.42
▸ MAOB P27338 2/20 0.41
▸ MAOA P21397 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ AKR1C3 P42330 1/20 0.41
▸ SRD5A2 P31213 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ SOS1 Q07889 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556425 1.00 LMNA (0.50) LMNAGAAKMT2AERN1LTA4H
SCHEMBL11288471 0.86 FFAR4 (0.43) ERN1FFAR4FFAR1MAOBMAOA
SCHEMBL5175967 0.86 SOS1 (0.44) KMT2AERN1FFAR4MAOBMAOA
SCHEMBL23709919 0.86 LMNA (0.50) LMNAGAAKMT2AERN1LTA4H
SCHEMBL20523126 0.81 LMNA (0.56) LMNAGAAERN1LTA4HFFAR4
SCHEMBL27720125 0.79 HSPB1 (0.58) KMT2AERN1FFAR1ALDH1A1CYP2C9
SCHEMBL6093640 0.79 ERN1 (0.61) LMNAGAAKMT2AERN1LTA4H
SCHEMBL30397192 0.79 LMNA (0.50) LMNAGAAKMT2AERN1LTA4H
SCHEMBL24189619 0.79 LMNA (0.50) LMNAGAAKMT2AERN1LTA4H
SCHEMBL28250579 0.79 KMT2A (0.50) LMNAGAAKMT2AERN1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-06-16 — — US disclosed
CN-106554334-B A kind of nematicide containing lactonic ring and its production and use 山东省联合农药工业有限公司 2017-09-22 — — CN disclosed
CN-106554335-B A kind of nematicide containing lactonic ring of transconfiguration and its production and use 山东省联合农药工业有限公司 2017-09-19 — — CN disclosed
EP-1859798-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2015-12-30 — — EP disclosed
US-8044090-B2 N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor ELI LILLY (US) 2011-10-25 — — US disclosed
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2009-12-10 — — US disclosed
EP-1859798-A1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2007-11-28 — — EP disclosed
EP-1379239-B1 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR LILLY CO ELI (US) 2007-09-12 — — EP disclosed
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR CHEN ZHAOGEN 2007-05-03 — — US disclosed
US-7157488-B2 N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US disclosed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN disclosed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP disclosed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO disclosed
US-4261920-A INSECTICIDES BAYER AKTIENGESELLSCHAFT (DE) 1981-04-14 — — US disclosed
US-4218469-A Combating arthropods with 3-phenoxy-fluoro-benzyl carboxylic acid esters BAYER AKTIENGESELLSCHAFT (DE) 1980-08-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B LMNA 4040/4885GAA 4200/4885KMT2A 1269/4885
US-20090306110-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B LMNA 4040/4885GAA 4200/4885KMT2A 1269/4885
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE PTDSS1, PTDSS2, SMPD1 LMNA 4163/4885GAA 2695/4885KMT2A 3060/4885
US-20070099909-A1 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR HTR6, HTR2C, HTR1B LMNA 4040/4885GAA 4200/4885KMT2A 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback